DHEA
HormonePreclinicalAlso known as: Dehydroepiandrosterone, 3β-hydroxy-5-androsten-17-one, Prasterone, Intrarosa, DHEA-S (sulfate form), Androstenolone, Transdehydroandrosterone
DHEA (dehydroepiandrosterone) is an endogenous steroid hormone synthesized primarily by the adrenal cortex (zona reticularis), with smaller amounts produced by the gonads and brain. It is the most abundant circulating steroid hormone in humans, vastly exceeding plasma concentrations of testosterone, cortisol, or estrogens — total plasma DHEA including its sulfated storage form DHEA-S reaches 1,000-3,000 μg/dL in young adults, orders of magnitude higher than cortisol (10-20 μg/dL) or testosterone (300-1,000 ng/dL in men, 15-70 ng/dL in women).
Overview
At A Glance
DHEA operates through multiple mechanistic pathways, reflecting its dual role as a direct neuroactive steroid and as a prohormone substrate for sex steroid synthesis. Understanding DHEA's effects requires distinguishing its intrinsic receptor-mediated activities from effects aris…
Mechanism of Action
DHEA operates through multiple mechanistic pathways, reflecting its dual role as a direct neuroactive steroid and as a prohormone substrate for sex steroid synthesis. Understanding DHEA's effects requires distinguishing its intrinsic receptor-mediated activities from effects arising through its metabolic conversion to androgens and estrogens.
Intracrine conversion to sex steroids — the prohormone function: DHEA is the quantitatively dominant substrate for peripheral (extra-gonadal) sex steroid synthesis in humans. The key conversion pathway: DHEA → androstenedione (via 3β-hydroxysteroid dehydrogenase) → testosterone (via 17β-hydroxysteroid dehydrogenase) → estradiol (via aromatase, CYP19A1) or to dihydrotestosterone (DHT) via 5α-reductase in androgen-sensitive tissues. The balance between androgenic and estrogenic conversion depends on tissue-specific expression of these enzymes — muscle and liver favor androgen conversion; adipose tissue favors aromatization to estradiol; skin converts to both androgens and DHT. In women, adrenal DHEA provides the major substrate for post-menopausal sex steroid synthesis in peripheral tissues (bone, skin, vagina, brain) after ovarian production ceases; the Labrie intracrinology framework established that post-menopausal women synthesize 75-90% of their sex steroids via peripheral DHEA conversion rather than from ovarian or adrenal direct secretion. In men, DHEA contributes ~5-10% of circulating testosterone and a larger fraction of tissue-specific DHT. Oral DHEA supplementation substantially increases these substrate pools; the pharmacological effect on sex steroid levels depends on dose, baseline endogenous production, body composition (more adipose = more aromatization), and individual enzyme variation.
Direct neuroactive steroid effects: DHEA and DHEA-S act directly on several neurotransmitter receptor systems in the brain, providing mechanistic basis for mood and cognitive effects independent of sex steroid conversion. (1) Negative allosteric modulation of GABA-A receptors: unlike most endogenous neurosteroids (allopregnanolone, pregnanolone) that positively modulate GABA-A and produce anxiolytic/sedative effects, DHEA-S antagonizes GABA-A signaling at higher concentrations, producing mild alerting/anxiogenic effects that contrast with the GABA-positive neurosteroids. This "anti-GABA" property contributes to DHEA's subjective alerting effects at higher doses. (2) Positive modulation of NMDA receptors: DHEA enhances NMDA receptor signaling, potentially contributing to cognitive effects on learning and memory. (3) Sigma-1 receptor activation: DHEA is an agonist at sigma-1 receptors, a neurotransmitter-independent modulator system implicated in depression, neurodegeneration, and cognitive function. Sigma-1 activation contributes to DHEA's antidepressant effects and neuroprotective properties. (4) Nuclear receptor interactions: DHEA binds and modulates several nuclear receptors including PPARα, PXR, and potentially others, though the extent of direct nuclear receptor-mediated effects remains under investigation.
Anti-glucocorticoid effects: DHEA has a functional "anti-cortisol" effect in many tissues, partly opposing glucocorticoid actions on immune function, metabolism, and CNS activity. The DHEA:cortisol ratio is proposed as an integrated index of adrenal balance, with low ratios (high cortisol, low DHEA) associated with stress-related conditions, immune suppression, and accelerated aging markers. This framework is invoked in "adrenal balance" clinical perspectives, though the specific clinical utility of DHEA:cortisol ratio measurement remains debated.
Immune modulation: DHEA directly and indirectly influences immune function. T-lymphocyte subsets, cytokine balance (favoring Th1 over Th2 in some contexts), natural killer cell activity, and inflammatory marker production are modulated by DHEA. The decline of DHEA with aging correlates with observed immune senescence — reduced vaccine responses, increased susceptibility to infections, and increased autoimmune phenomena. Whether DHEA replacement reverses immune senescence in healthy older adults is unsettled; some specific conditions (lupus, severe adrenal insufficiency) show immune benefits from DHEA replacement.
Metabolic effects: DHEA modulates glucose metabolism (generally improving insulin sensitivity in some populations), lipid metabolism (modest effects on cholesterol fractions), and body composition (effects on muscle-fat balance in specific populations). These metabolic effects are partly direct and partly mediated through sex steroid conversion. The landmark Nair 2006 DHEA and Aging Trial found no significant metabolic benefits in healthy older adults, but specific subpopulations (adrenal insufficiency patients, some post-menopausal women) show more favorable responses.
Pharmacokinetics:
Oral bioavailability: oral DHEA has modest bioavailability (~20-50%) due to substantial first-pass hepatic metabolism. Peak plasma DHEA typically occurs 60-120 minutes after oral dose. Elimination half-life of DHEA itself is short (15-30 minutes) as it is rapidly converted to DHEA-S (which has much longer half-life, 7-10 hours) and to downstream steroids. Standard oral doses of 25-100mg reliably increase plasma DHEA-S 2-5 fold above baseline for healthy adults and produce more dramatic increases in deficient individuals.
Metabolic conversion: following absorption, DHEA is rapidly sulfated to DHEA-S (the dominant circulating storage form), hydrolyzed back to free DHEA as needed, converted to androstenedione and downstream androgens/estrogens in peripheral tissues, and metabolized via various pathways including 7-hydroxylation (producing 7α- and 7β-hydroxy-DHEA, metabolites with independent biological activities in some studies).
Sex differences: women have approximately 50% of men's DHEA levels at baseline in young adulthood; this difference diminishes with age as both sexes decline. Women typically experience more pronounced androgenic effects from supplemental DHEA at equivalent doses (their baseline androgen levels are lower, so DHEA-derived androgen increase is proportionally greater). Men typically experience more pronounced estrogenic effects at very high doses (aromatization of excess DHEA-derived androgens to estradiol, particularly in adipose-tissue-heavy individuals).
Age relevance: the dramatic age-related decline of DHEA provides a clear biomarker for adrenopause, and individual DHEA-S measurement (standard commercial lab test) allows assessment of whether a specific person is in the lower range for their age. Low DHEA-S in younger adults may suggest adrenal insufficiency warranting evaluation; in older adults, low-normal DHEA-S is expected and doesn't necessarily indicate replacement need.
Topical/transdermal absorption: topical DHEA (0.5-1% cream applied to skin) provides transdermal absorption with avoidance of first-pass hepatic metabolism, producing more sustained physiological-range increases. Some practitioners prefer topical formulations for this reason. Vaginal DHEA (Intrarosa 6.5mg) produces local tissue effects with minimal systemic absorption — the basis for its FDA-approved vaginal atrophy indication.
DHEA vs DHEA-S: both forms are commercially available; DHEA-S (the sulfated form) has longer half-life but less efficient CNS penetration. Most clinical trials use DHEA (non-sulfated form); supplement products are typically DHEA unless otherwise labeled.
Interactions with other hormones: DHEA interacts with the broader HPA axis, HPG axis, and thyroid axis. High-dose DHEA can modestly suppress ACTH and cortisol (via negative feedback on adrenal), affect LH/FSH balance, and has minor thyroid interactions. Chronic high-dose use warrants hormonal panel monitoring.
Key mechanistic takeaways: DHEA is not a single-target pharmacological agent but a pleiotropic hormone whose effects derive from: (1) substrate provision for peripheral sex steroid synthesis (major effect in post-menopausal women, meaningful effect in men), (2) direct neuroactive steroid actions via GABA-A antagonism, NMDA enhancement, and sigma-1 agonism, (3) immune modulation, (4) anti-glucocorticoid effects, and (5) metabolic effects. The clinical response to DHEA supplementation depends heavily on baseline endocrine state, sex, age, body composition, and specific enzyme tissue expression — explaining why DHEA helps dramatically in adrenal-insufficient states but shows little benefit in healthy older adults.
Overview
DHEA (dehydroepiandrosterone) is an endogenous steroid hormone synthesized primarily by the adrenal cortex (zona reticularis), with smaller amounts produced by the gonads and brain. It is the most abundant circulating steroid hormone in humans, vastly exceeding plasma concentrations of testosterone, cortisol, or estrogens — total plasma DHEA including its sulfated storage form DHEA-S reaches 1,000-3,000 μg/dL in young adults, orders of magnitude higher than cortisol (10-20 μg/dL) or testosterone (300-1,000 ng/dL in men, 15-70 ng/dL in women). Despite this abundance, DHEA's physiological role remained enigmatic through much of the 20th century, and it was long described as a "precursor hormone without clear intrinsic activity." Contemporary understanding has substantially revised this view: DHEA serves as the substrate pool for peripheral sex steroid synthesis in extra-gonadal tissues (particularly skin, brain, immune cells, and post-menopausal ovarian remnants), acts as a neuroactive steroid with direct effects on GABA-A and NMDA receptors, modulates immune function, and has its own metabolic and anti-inflammatory activities independent of sex steroid conversion.
The characteristic physiological feature of DHEA is its dramatic age-related decline — the steepest of any circulating hormone. DHEA and DHEA-S peak at ages 20-30 and decline progressively to approximately 10-20% of young-adult values by age 70-80. This phenomenon, termed "adrenopause," is distinct from menopause and andropause and affects both sexes similarly. The decline correlates temporally with many age-related changes including decreased muscle mass, decreased bone density, decreased libido, cognitive changes, and immune senescence — leading to the hypothesis that DHEA decline contributes to or represents the endocrine signal of aging, and that DHEA replacement might be rejuvenating. This hypothesis has driven extensive DHEA research over the past 30 years, producing a mixed evidence base: some specific populations (Addison's disease, severe adrenal insufficiency) benefit clearly from DHEA replacement; some conditions (depression, vaginal atrophy, poor responder IVF) have moderate positive evidence; but the broader "anti-aging" claims for DHEA supplementation in healthy adults have largely not been supported by controlled trials.
DHEA is chemically classified as a 17-ketosteroid and serves as a prohormone for both androgens and estrogens via peripheral conversion. The pathway: DHEA → androstenedione → testosterone (via 17β-HSD) → estradiol (via aromatase). Tissues expressing the conversion enzymes can generate local androgens and estrogens from circulating DHEA even when gonadal production is absent or insufficient — this is the basis for DHEA's role in providing sex steroid support to post-menopausal women, aging men with decreased testosterone, and patients with primary adrenal insufficiency where adrenal androgen synthesis fails. The concept of intracrinology — local cellular production of active hormones from circulating precursors — was significantly developed around DHEA biology by Fernand Labrie and colleagues at Laval University, Quebec.
Regulatory status varies globally: In the United States, DHEA is classified as a dietary supplement and available without prescription in doses typically ranging from 5mg to 100mg, despite being a potent hormone with clear physiological effects. In the European Union, UK, Canada, and Australia, DHEA is a prescription-only medication reflecting those regulators' assessment of its hormonal potency and risk profile. Prasterone (pharmaceutical-grade DHEA) is available as Intrarosa (FDA-approved 2016) for vaginal atrophy, and in some jurisdictions for specific hormonal-deficiency conditions. The U.S. Anti-Doping Agency (USADA) and World Anti-Doping Agency (WADA) classify DHEA as a prohibited substance in competitive sport given its androgenic and anabolic effects.
Clinical evidence is strongest for specific deficiency-state and targeted indications: (1) Primary adrenal insufficiency (Addison's disease): Arlt et al. 1999 (New England Journal of Medicine, PMID: 10498490) established that DHEA 50mg/day in women with Addison's disease improves mood, well-being, sexual function, and body composition — DHEA is now standard replacement therapy alongside glucocorticoid and mineralocorticoid replacement in Addison's patients; (2) Vaginal atrophy / genitourinary syndrome of menopause: Labrie et al. 2009 and subsequent trials established that intravaginal prasterone (Intrarosa 6.5mg/day intravaginal) improves vaginal dryness, dyspareunia, and vulvar atrophy in post-menopausal women — FDA-approved 2016 for this indication; (3) Depression: Wolkowitz et al. 1999and Schmidt et al. 2005documented antidepressant effects in midlife-onset depression with DHEA 90-450mg/day over 6 weeks; (4) IVF in poor responders: DHEA 75mg/day for 3+ months has been studied for improving ovarian response in poor responder IVF cycles, with mixed but moderately positive evidence (Wiser 2010); (5) Schizophrenia adjunctive and (6) lupus adjunctive have moderate evidence bases in specific subpopulations.
Evidence is less clear or negative for: general anti-aging in healthy older adults (multiple trials including the landmark Nair et al. 2006 DHEA and Aging Trial in NEJM, found no significant benefits on body composition, physical performance, or quality of life in healthy older adults given DHEA 50-75mg for 2 years), cognitive enhancement in healthy adults, athletic performance (evidence is weak plus DHEA is a banned substance in sport), weight loss, and "adrenal fatigue" (a non-medical concept without clinical validity). The landmark negative result of the Nair 2006 trial in particular substantially dampened enthusiasm for broad DHEA supplementation in healthy aging adults, though specific deficiency contexts remain clearly supported.
DHEA's status as a widely-available OTC hormone in the US creates both opportunities and risks. The opportunities: individuals with subclinical adrenal insufficiency, perimenopausal/postmenopausal women with specific genitourinary symptoms, and individuals with clinical depression in midlife may derive benefit under appropriate clinical supervision. The risks: high-dose DHEA supplementation without clinical indication may produce androgenic side effects (acne, hirsutism, male-pattern hair loss in susceptible individuals, voice changes in women), estrogenic effects in men (gynecomastia), and theoretical concerns about hormone-sensitive cancers. Individuals with breast cancer, prostate cancer, or hormone-sensitive malignancies should avoid DHEA supplementation unless specifically directed by oncology.
See also Pregnenolone, Testosterone, Melatonin, Magnesium, Ashwagandha, Fadogia Agrestis, and Tongkat Ali for adjacent hormonal-support and androgenic-tuning compounds. This overview is educational only and is not medical advice — DHEA is a potent hormone with systemic endocrine effects, and any use for clinical conditions warrants physician supervision.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
DHEA has multiple important contraindications and requires clinical caution across multiple populations given its hormonal potency and conversion to androgens and estrogens.
Absolute or strong relative contraindications:
Hormone-sensitive cancers (absolute contraindication):
- Breast cancer (active, remission, or high-risk family history): DHEA converts to estradiol via aromatase; estradiol is the primary driver of ER+ breast cancer. Avoid DHEA in any woman with active breast cancer, history of breast cancer, high-risk family history, or known BRCA mutations.
- Prostate cancer (active, remission, or elevated PSA): DHEA converts to testosterone and DHT; these androgens are primary drivers of prostate cancer. Avoid DHEA in men with active prostate cancer, history of prostate cancer, elevated PSA (>4 ng/mL or concerning trajectory), or prostate nodule.
- Endometrial cancer: estrogenic conversion is concerning. Avoid.
- Ovarian cancer: hormone-sensitive subtypes are concerning. Avoid unless specifically directed by oncology.
- Hormone-sensitive tumors (generally): discuss with oncology before considering DHEA.
Pregnancy and lactation (absolute contraindication):
- Pregnancy: DHEA supplementation during pregnancy is contraindicated outside specialized reproductive endocrinology protocols (IVF contexts where DHEA is used only until pregnancy is established, then discontinued). Fetal androgen exposure is a serious concern, particularly for female fetal development.
- Lactation: DHEA passes into breast milk; hormonal effects on nursing infants are concerning. Avoid.
Pediatric use (strong relative contraindication):
- DHEA is not appropriate for children and adolescents outside specific pediatric endocrinology indications (congenital adrenal hyperplasia, specific adrenal deficiency)
- Premature puberty concerns with any pediatric sex steroid supplementation
- Children who accidentally ingest adult DHEA supplements should be evaluated for hormonal exposure
Major relative contraindications warranting specific caution:
Bipolar disorder:
- Rare reports of hypomania or mania triggered by DHEA, particularly at higher doses
- Avoid in active bipolar disorder unless under psychiatric supervision
- Caution in bipolar spectrum disorders
Untreated or severe depression with suicidality:
- DHEA can paradoxically worsen depression in some individuals
- Not first-line; use only under psychiatric supervision if at all
Polycystic ovary syndrome (PCOS) with androgenic symptoms:
- PCOS patients already have elevated androgen symptoms (hirsutism, acne, alopecia)
- Adding DHEA often worsens these symptoms
- Generally avoid in active PCOS unless reproductive endocrinology directs
Severe liver disease or severe hepatic impairment:
- DHEA is extensively hepatically metabolized
- Severe cirrhosis, hepatic encephalopathy, or acute liver failure warrants avoidance
- Moderate liver impairment warrants dose reduction and caution
Severe renal impairment:
- Moderate reduction in dose may be prudent in severe CKD (CrCl <30 mL/min)
Cardiovascular disease, uncontrolled hypertension:
- Variable effects on BP and metabolic parameters
- Monitor carefully if starting
- Not absolute contraindication but caution warranted
Diabetes, particularly poorly controlled:
- Variable effects on insulin sensitivity
- Monitor glucose when starting
Active androgenic alopecia, hirsutism, or voice changes:
- DHEA will likely worsen these conditions
- Discuss with dermatology or endocrinology
Competitive athletics:
- DHEA is on the WADA Prohibited List, NCAA banned substance list, and most professional sports league lists
- Athletes competing in drug-tested sports must avoid DHEA
Drug interactions requiring coordination:
Insulin and diabetes medications: monitor blood glucose when starting; may require medication adjustment.
Antihypertensive medications: variable effects on BP; monitor.
Warfarin and anticoagulants: isolated reports of INR changes; monitor particularly in the first month of DHEA initiation or dose change.
Testosterone replacement therapy (TRT): adding DHEA to TRT is usually redundant and risks supraphysiological testosterone. Coordinate with TRT prescriber.
Estrogen replacement therapy (HRT): DHEA adds to total estrogen exposure via aromatization. Review total hormonal picture.
SERM medications (tamoxifen, raloxifene): DHEA interferes with the anti-estrogen purpose; avoid combining without oncology guidance.
Aromatase inhibitors (anastrozole, letrozole, exemestane): DHEA provides substrate for aromatase; combining defeats the purpose. Avoid unless specifically directed.
5α-reductase inhibitors (finasteride, dutasteride): DHEA provides DHT substrate; may blunt clinical effect. Discuss with prescriber.
Corticosteroids: DHEA modestly opposes glucocorticoid effects; generally not clinically significant at standard doses.
Antipsychotics: DHEA has been studied as schizophrenia adjunct; otherwise neutral interaction.
Lithium: theoretical interaction; limited clinical data.
Anticonvulsants affecting steroid metabolism (phenytoin, carbamazepine, phenobarbital): may alter DHEA metabolism; monitor response.
Oral contraceptives: effects on overall hormonal balance; discuss with gynecology.
MAO inhibitors: theoretical concerns about sympathomimetic effects from increased androgen exposure; caution.
Alcohol: no direct pharmacokinetic interaction but both affect hepatic metabolism; moderate use.
Thyroid medications: generally neutral interaction.
When to stop DHEA and seek medical evaluation:
- Breast lump, unusual mass, or tenderness in either sex
- Prostate symptoms (urinary changes, pelvic discomfort)
- Unusual bleeding
- Severe mood changes (depression, hypomania, severe anxiety)
- Development of significant androgenic symptoms not resolved with dose reduction (persistent acne, hirsutism, voice changes, male-pattern hair loss)
- Gynecomastia development in men
- Breakthrough bleeding or significant menstrual changes in women
- Pregnancy or pregnancy planning
- New diagnosis of hormone-sensitive cancer
- New major medical diagnosis warranting medication review
- Abnormal hormonal lab trends (supraphysiological levels, concerning androgen/estrogen ratios)
- Abnormal liver function tests
- Any concerning cardiovascular, metabolic, or mental health changes
Special populations and considerations:
Menopausal transition (perimenopause):
- Variable hormonal effects; individual response unpredictable
- Caution with symptomatic perimenopausal women — DHEA may disrupt natural fluctuations
- Discuss with gynecology
Post-menopause with HRT considerations:
- DHEA may integrate with or complicate standard HRT
- Discuss total hormonal picture with gynecology
- Target population for potential benefit but requires individualized assessment
Low libido and sexual dysfunction:
- Multifactorial conditions requiring complete workup
- DHEA is one of multiple possible interventions, not first-line
- Endocrinology or sexual medicine evaluation recommended
Chronic fatigue states:
- DHEA often tried but rarely the full answer
- Comprehensive medical evaluation is primary
- "Adrenal fatigue" is not medically validated; true adrenal insufficiency requires specific diagnosis
Obesity:
- More aromatase activity in adipose tissue; men with higher body fat may experience greater estrogenic conversion from DHEA
- Monitor estradiol in obese men on DHEA
- Weight loss may reduce DHEA-related estrogenic effects
Elderly:
- Generally lower doses appropriate
- More careful monitoring of hormonal, cardiovascular, and metabolic parameters
- More frequent drug interaction reviews
Athletes and fitness contexts:
- Competitive athletes must avoid DHEA (banned substance)
- Recreational fitness users should weigh androgenic side effects vs perceived performance benefits
- Evidence for performance enhancement in non-deficient individuals is weak
Transgender populations:
- Complex hormonal considerations; typically coordinated with endocrinology
- DHEA not standard in transition-related hormone therapy but may be used for specific indications
Long-term safety summary:
- Multi-year safety data beyond 2-4 years at doses >50mg/day is limited
- Theoretical hormone-sensitive cancer concerns with chronic high-dose use
- Periodic reassessment of ongoing need and response is essential
- Lower doses (25mg/day) for appropriate indications have more favorable long-term safety profile
Final summary: DHEA is a potent hormone with clear contraindications (hormone-sensitive cancer, pregnancy, pediatric use), significant relative contraindications (bipolar, PCOS, severe liver disease, competitive athletics), and meaningful drug interactions. Its use should be driven by clinical indication (confirmed low DHEA-S, specific conditions with evidence) rather than general anti-aging claims. Physician oversight is particularly valuable given the hormonal potency and need for individualization.
This is general educational content, not individualized medical advice. Anyone considering DHEA supplementation should consult a physician familiar with hormonal therapies, obtain appropriate baseline labs, and commit to ongoing monitoring.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for DHEA.
Research Score
19864 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is DHEA and should I take it?
DHEA (dehydroepiandrosterone) is a hormone produced by your adrenal glands that serves as a building block for testosterone and estrogen in peripheral tissues. It's most abundant in young adulthood and declines dramatically with age — by 70-80, your DHEA is typically 10-20% of young-adult levels. You should consider DHEA only if you have specific indications: documented low DHEA-S on a lab test, a clinical condition with evidence supporting DHEA (midlife depression, Addison's disease, vaginal atrophy, IVF as poor responder), or physician-directed replacement. You should NOT take DHEA just because you're aging or feeling tired — the landmark Nair 2006 NEJM trial (PMID: 17050890) found no significant benefits in healthy older adults for body composition, physical performance, or quality of life over 2 years. DHEA is a hormone, not a generic supplement; it should have a clear rationale before starting.
What dose of DHEA should women take?
Women should typically start at 5mg/day oral morning dose. Women have baseline androgen levels 10-20× lower than men, so their DHEA requirements and sensitivity are much lower. Most women settle at 10-25mg/day for general low-DHEA-S supplementation or Addison's replacement. Higher doses (75-300mg/day) are used only for specific indications like IVF poor responders (Wiser 2010, PMID: 20689155) or midlife-onset depression (Schmidt 2005, PMID: 15699295) under physician supervision. Women commonly experience androgenic side effects (acne, hirsutism, oily skin) at doses above 25mg — these require dose reduction. Target lab value: DHEA-S in the upper half of age-appropriate reference range, not supraphysiological.
What dose of DHEA should men take?
Men typically start at 25mg/day oral morning dose. Most men settle at 25-50mg/day for general low-DHEA-S supplementation. Higher doses (75mg+) are rarely needed and often produce estrogenic conversion (aromatization to estradiol) which can cause gynecomastia, water retention, and other estrogenic effects — particularly in men with higher body fat percentage. Target lab value: DHEA-S in the upper half of age-appropriate reference range. Monitor estradiol periodically — if estradiol rises significantly, reduce DHEA dose. For men on testosterone replacement therapy (TRT), DHEA is usually redundant and risks supraphysiological androgens; coordinate with your TRT prescriber.
Is DHEA safe long-term?
For appropriate clinical indications at moderate doses (25-50mg/day), DHEA has an acceptable long-term safety profile based on decades of European prescription use and US supplementation. However, long-term safety data beyond 2-4 years at higher doses (>100mg/day) is limited. Theoretical concerns about hormone-sensitive cancer development with chronic supraphysiological exposure warrant caution. Key long-term considerations: (1) avoid if you have history of hormone-sensitive cancer (breast, prostate, endometrial); (2) periodic monitoring of hormone levels, metabolic parameters, and age-appropriate cancer screenings (mammogram, PSA, pelvic exam); (3) use the lowest dose that achieves target clinical effect; (4) reassess ongoing need every 6-12 months; (5) consider periodic breaks to confirm ongoing benefit. Lower doses (25mg) for documented clinical indications are substantially safer long-term than higher doses (100mg+) used speculatively.
Does DHEA help with depression?
Yes, for midlife-onset depression specifically, with moderate evidence. Wolkowitz et al. 1999 (PMID: 10320683) and Schmidt et al. 2005 (PMID: 15699295) documented antidepressant effects in midlife depression (ages 40-65) with DHEA 90-300mg/day over 6 weeks — 50% response rate vs 13% placebo in Schmidt trial. The dose range for depression (90-300mg) is substantially higher than typical supplementation and approaches levels that produce significant androgenic/estrogenic side effects. This should be done under psychiatric supervision as adjunct to standard depression care (therapy, lifestyle, often antidepressants). DHEA is NOT first-line depression treatment and is NOT appropriate for all depression — it's specifically studied in midlife-onset depression with possible adrenal/hormonal contribution. For general depression, conventional approaches (SSRIs, therapy, exercise, sleep) are primary.
Does DHEA cause acne or hair loss?
Yes — these are common androgenic side effects, particularly at higher doses. Acne (facial and back) is reported in 20-30% of women at doses above 25mg/day and in men at doses above 50mg/day. Male-pattern scalp hair thinning can occur in both sexes if they have androgen-sensitive alopecia genetics — DHEA supplementation provides substrate for DHT conversion, which is the primary hormone driving androgenic alopecia. Hirsutism (facial hair growth in women) is common at higher doses. Management: (1) reduce dose; (2) discontinue if side effects persist despite lower dose; (3) monitor lab testosterone to confirm it's not supraphysiological; (4) topical/transdermal DHEA may produce fewer androgenic side effects than oral for women. Individuals with existing androgenic alopecia, acne-prone skin, or PCOS should avoid or use very low doses with careful monitoring.
Is DHEA good for fertility or IVF?
There is moderate evidence that DHEA 75mg/day for 3+ months before IVF stimulation improves outcomes in poor responders — women with diminished ovarian reserve (DOR) or previous failed IVF cycles. Wiser et al. 2010 (PMID: 20689155) and Gleicher et al. 2010 (PMID: 20570241) documented improved oocyte yield, embryo quality, and pregnancy rates. The proposed mechanism: DHEA supports follicular androgen milieu, enhancing FSH responsiveness. Many reproductive endocrinology clinics now include DHEA in poor-responder protocols. However: (1) this is for poor responders specifically, not general fertility; (2) for women with normal ovarian reserve, DHEA likely provides no benefit and may cause side effects; (3) physician supervision is essential; (4) discontinue DHEA once pregnancy is established. DHEA is not indicated for male fertility enhancement beyond limited evidence for specific populations.
Can I take DHEA with other hormones like testosterone?
Generally not recommended without medical supervision. DHEA + testosterone replacement therapy (TRT) is typically redundant — TRT provides direct testosterone, and adding DHEA provides more androgen precursor, risking supraphysiological testosterone levels. Coordinate with your TRT prescriber. DHEA + estrogen replacement therapy (HRT) adds to total estrogen exposure via aromatization; discuss with gynecologist. DHEA + aromatase inhibitors is contraindicated — DHEA provides substrate that the inhibitors block, defeating their purpose (particularly relevant for breast cancer patients). DHEA + 5α-reductase inhibitors (finasteride, dutasteride) — DHEA increases DHT substrate that these drugs partially block; may reduce clinical effect. DHEA + SERM medications (tamoxifen, raloxifene) — avoid without oncology guidance. DHEA + pregnenolone or herbal testosterone support can produce supraphysiological hormone levels; monitor carefully. For most men considering DHEA alongside other hormonal interventions, comprehensive evaluation is warranted.
Is DHEA banned for athletes?
Yes. DHEA is on the World Anti-Doping Agency (WADA) Prohibited List and is banned in and out of competition for athletes covered by WADA. The NCAA banned substance list also includes DHEA. Most professional sports leagues (MLB, NFL, NBA, etc.) prohibit DHEA. Olympic athletes, college athletes, professional athletes, and anyone subject to drug testing under these programs must avoid all forms of DHEA — including OTC supplements, compounded preparations, and prescription forms (except for documented medical use with appropriate TUE — Therapeutic Use Exemption). A positive test for DHEA metabolites can result in multi-year competition bans. Recreational and non-competitive athletes are not subject to these testing programs but should understand that performance benefits from DHEA in non-deficient individuals are weak at best, while side effects are real.
What's the difference between DHEA and pregnenolone?
Both are upstream steroid hormones in the adrenal synthesis pathway, but serve different functions. Pregnenolone is the primary precursor for both corticosteroid (cortisol) and DHEA synthesis pathways — it's the 'master' steroid from which all other steroid hormones derive. Pregnenolone supplementation can theoretically support both cortisol and DHEA pathways. DHEA is specifically the precursor for sex steroids (testosterone, estrogen) and has direct neuroactive effects via GABA-A, NMDA, and sigma-1 receptors. Differences in practice: (1) pregnenolone tends to produce more subtle effects with less androgenic/estrogenic conversion; (2) DHEA produces more specific sex hormone effects; (3) pregnenolone has some unique neurological applications (memory, cognition); (4) DHEA has more specific clinical evidence for depression, vaginal atrophy, IVF, and lupus. Some clinicians use both together for comprehensive hormonal support in confirmed adrenal dysfunction. For most users, starting with one at a time allows assessment of individual response.
Research Tools
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
